Ascentage Pharma expands equity incentives for key personnel

Ascentage Pharma Group International has announced the further grant of 1,304,457 restricted share units (RSUs) under its 2022 RSU Scheme to 146 selected persons, effective November 26, 2025. This grant represents approximately 0.35% of the company's issued share capital. Notable recipients include Dr. Yang Dajun (143,363 RSUs), two non-executive directors (55,930 RSUs), six independent non-executive directors (170,445 RSUs), Dr. Zhai Yifan (127,201 RSUs), and eight service providers (170,000 RSUs). The closing price of H Shares on the grant date was HK$63.35, with no purchase price required from recipients.

Additionally, the company granted 736,607 options under its Post IPO Share Option Scheme to 34 grantees, also effective November 26, 2025. The exercise price for these options is HK$63.35 per share, and they will be exercisable over ten years. This option grant represents approximately 0.20% of the company's issued share capital. Key option recipients include Dr. Yang Dajun (143,363 options), Dr. Zhai Yifan (103,364 options), and seven service providers (80,000 options).

The grants aim to incentivize existing directors and attract, motivate, and retain skilled personnel and consultants, aligning with the company's long-term growth strategy. Vesting for both RSUs and options is subject to annual performance reviews and various time-based tranches, with some vesting periods less than 12 months for core talents.